BACKGROUND:Caffeine attenuates the coronary hyperemic response to adenosine by competitive A₂(A) receptor blockade. This study aims to determine whether oral caffeine administration compromises diagnostic accuracy in patients undergoing vasodilator stress myocardial perfusion imaging (MPI) withregadenoson, a selective adenosine A(2A) agonist. METHODS: This multicenter, randomized, double-blind, placebo-controlled, parallel-group study includes patients with suspected coronary artery disease who regularly consume caffeine. Each participant undergoes three SPECT MPI studies: a rest study on day 1 (MPI-1); a regadenoson stress study on day 3 (MPI-2), and a regadenoson stress study on day 5 with double-blind administration of oral caffeine 200 or 400 mg or placebo capsules (MPI-3; n = 90 per arm). Only participants with ≥ 1 reversible defect on the second MPI study undergo the subsequent stress MPI test. The primary endpoint is the difference in the number of reversible defects on the two stress tests using a 17-segment model. Pharmacokinetic/pharmacodynamic analyses will evaluate the effect of caffeine on the regadenoson exposure-response relationship. Safety will also be assessed. CONCLUSION: The results of this study will show whether the consumption of caffeine equivalent to 2-4 cups of coffee prior to an MPI study with regadenoson affects the diagnostic validity of stress testing (ClinicalTrials.gov number, NCT00826280).
RCT Entities:
BACKGROUND:Caffeine attenuates the coronary hyperemic response to adenosine by competitive A₂(A) receptor blockade. This study aims to determine whether oral caffeine administration compromises diagnostic accuracy in patients undergoing vasodilator stress myocardial perfusion imaging (MPI) with regadenoson, a selective adenosine A(2A) agonist. METHODS: This multicenter, randomized, double-blind, placebo-controlled, parallel-group study includes patients with suspected coronary artery disease who regularly consume caffeine. Each participant undergoes three SPECT MPI studies: a rest study on day 1 (MPI-1); a regadenoson stress study on day 3 (MPI-2), and a regadenoson stress study on day 5 with double-blind administration of oral caffeine 200 or 400 mg or placebo capsules (MPI-3; n = 90 per arm). Only participants with ≥ 1 reversible defect on the second MPI study undergo the subsequent stress MPI test. The primary endpoint is the difference in the number of reversible defects on the two stress tests using a 17-segment model. Pharmacokinetic/pharmacodynamic analyses will evaluate the effect of caffeine on the regadenoson exposure-response relationship. Safety will also be assessed. CONCLUSION: The results of this study will show whether the consumption of caffeine equivalent to 2-4 cups of coffee prior to an MPI study with regadenoson affects the diagnostic validity of stress testing (ClinicalTrials.gov number, NCT00826280).
Authors: Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Warren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani Journal: Circulation Date: 2002-01-29 Impact factor: 29.690
Authors: H William Strauss; D Douglas Miller; Mark D Wittry; Manuel D Cerqueira; Ernest V Garcia; Abdulmassi S Iskandrian; Heinrich R Schelbert; Frans J Wackers; Helena R Balon; Otto Lang; Josef Machac Journal: J Nucl Med Technol Date: 2008-08-14
Authors: J Zablocki; V Palle; B Blackburn; E Elzein; G Nudelman; S Gothe; Z Gao; Z Li; S Meyer; L Belardinelli Journal: Nucleosides Nucleotides Nucleic Acids Date: 2001 Apr-Jul Impact factor: 1.381
Authors: Eliana Reyes; Chee Y Loong; Mark Harbinson; Jackie Donovan; Constantinos Anagnostopoulos; S Richard Underwood Journal: J Am Coll Cardiol Date: 2008-12-09 Impact factor: 24.094
Authors: Rakesh N Patel; Roque B Arteaga; Mahendra K Mandawat; John W Thornton; Vincent J B Robinson Journal: South Med J Date: 2007-10 Impact factor: 0.954
Authors: Joseph C Lee; John F Fraser; Adrian G Barnett; Leslie P Johnson; Melinda G Wilson; Catherine M McHenry; Darren L Walters; Christopher R Warnholtz; Frederick A Khafagi Journal: J Nucl Cardiol Date: 2012-06 Impact factor: 5.952
Authors: Gong Zhao; Suhua Zhang; John C Shryock; Xiaobin Xu; Manuel Ochoa; Thomas H Hintze; Luiz Belardinelli Journal: J Nucl Cardiol Date: 2011-12-02 Impact factor: 5.952